[1] RAGHU G, COLLARD H R, EGAN J J, et al.An official ATS/ERS/JRS/ALAT statement:idiopathic pulmonary fibrosis:evidence-based guidelines for diagnosis and management[J].Am J Respir Crit Care Med, 2011, 183(6):788-824.
[2] 张海霞, 倪晓琴, 高永丽.多靶点护理干预对实施呼吸机治疗的特发性肺纤维化患者肺部并发症的影响[J].现代医学, 2020, 48(7):897-900.
[3] WUYTS W A, AGOSTINI C, ANTONIOU K M, et al.The pathogenesis of pulmonary fibrosis:a moving target[J].Eur Respir J, 2013, 41(5):1207-1218.
[4] KOLAHIAN S, FERNANDEZ I E, EICKELBERG O, et al.Immune mechanisms in pulmonary fibrosis[J].Am J Respir Cell Mol Biol, 2016, 55(3):309-322.
[5] KINDER B W, BROWN K K, SCHWARZ M I, et al.Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis[J].Chest, 2008, 133(1):226-232.
[6] CHRISTOPHERSON K 2ND, HROMAS R.Chemokine regulation of normal and pathologic immune responses[J].Stem Cells, 2001, 19(5):388-396.
[7] KOLACZKOWSKA E, KUBES P.Neutrophil recruitment and function in health and inflammation[J].Nat Rev Immunol, 2013, 13(3):159-175.
[8] CHAPMAN R W, PHILLIPS J E, HIPKIN R W, et al.CXCR2 antagonists for the treatment of pulmonary disease[J].Pharmacol Ther, 2009, 121(1):55-68.
[9] PETRI B, SANZ M J.Neutrophil chemotaxis[J].Cell Tissue Res, 2018, 371(3):425-436.
[10] RUSSO R C, GUABIRABA R, GARCIA C C, et al.Role of the chemokine receptor CXCR2 in bleomycin-induced pulmonary inflammation and fibrosis[J].Am J Respir Cell Mol Biol, 2009, 40(4):410-421.
[11] KUNKEL S L, STANDIFORD T, KASAHARA K, et al.Interleukin-8(IL-8):the major neutrophil chemotactic factor in the lung[J].Exp Lung Res, 1991, 17(1):17-23.
[12] LYNCH J P 3RD, STANDIFORD T J, ROLFE M W, et al.Neutrophilic alveolitis in idiopathic pulmonary fibrosis.The role of interleukin-8[J].Am Rev Respir Dis, 1992, 145(6):1433-1439.
[13] TSOUTSOU P G, GOURGOULIANIS K I, PETINAKI E, et al.Cytokine levels in the sera of patients with idiopathic pulmonary fibrosis[J].Respir Med, 2006, 100(5):938-945.
[14] XAUBET A, AGUSTI C, LUBURICH P, et al.Interleukin-8 expression in bronchoalveolar lavage cells in the evaluation of alveolitis in idiopathic pulmonary fibrosis[J].Respir Med, 1998, 92(2):338-344.
[15] STRIETER R M, GOMPERTS B N, KEANE M P.The role of CXC chemokines in pulmonary fibrosis[J].J Clin Invest, 2007, 117(3):549-556.
[16] KAWABATA K, HAGIO T, MATSUOKA S.The role of neutrophil elastase in acute lung injury[J].Eur J Pharmacol, 2002, 451(1):1-10.
[17] VOYNOW J A, SHINBASHI M.Neutrophil elastase and chronic lung disease[J].Biomolecules, 2021, 11(8):1065.
[18] HIRCHE T O, CROUCH E C, ESPINOLA M, et al.Neutrophil serine proteinases inactivate surfactant protein D by cleaving within a conserved subregion of the carbohydrate recognition domain[J].J Biol Chem, 2004, 279(26):27688-27698.
[19] YAMANOUCHI H, FUJITA J, HOJO S, et al.Neutrophil elastase:alpha-1-proteinase inhibitor complex in serum and bronchoalveolar lavage fluid in patients with pulmonary fibrosis[J].Eur Respir J, 1998, 11(1):120-125.
[20] CHUA F, DUNSMORE S E, CLINGEN P H, et al.Mice lacking neutrophil elastase are resistant to bleomycin-induced pulmonary fibrosis[J].Am J Pathol, 2007, 170(1):65-74.
[21] TAKEMASA A, ISHII Y, FUKUDA T.A neutrophil elastase inhibitor prevents bleomycin-induced pulmonary fibrosis in mice[J].Eur Respir J, 2012, 40(6):1475-1482.
[22] LEE K Y, HO S C, LIN H C, et al.Neutrophil-derived elastase induces TGF-beta1 secretion in human airway smooth muscle via NF-kappaB pathway[J].Am J Respir Cell Mol Biol, 2006, 35(4):407-414.
[23] GREGORY A D, KLIMENT C R, METZ H E, et al.Neutrophil elastase promotes myofibroblast differentiation in lung fibrosis[J].J Leukoc Biol, 2015, 98(2):143-152.
[24] SUZUKI T, MORAES T J, VACHON E, et al.Proteinase-activated receptor-1 mediates elastase-induced apoptosis of human lung epithelial cells[J].Am J Respir Cell Mol Biol, 2005, 33(3):231-247.
[25] KRISTENSEN J H, KARSDAL M A, SAND J M, et al.Serological assessment of neutrophil elastase activity on elastin during lung ECM remodeling[J].BMC Pulm Med, 2015, 15:53.
[26] MAHALANOBISH S, SAHA S, DUTTA S, et al.Matrix metalloproteinase:an upcoming therapeutic approach for idiopathic pulmonary fibrosis[J].Pharmacol Res, 2020, 152:104591.
[27] KAPOOR C, VAIDYA S, WADHWAN V, et al.Seesaw of matrix metalloproteinases(MMPs)[J].J Cancer Res Ther, 2016, 12(1):28-35.
[28] CRAIG V J, ZHANG L, HAGOOD J S, et al.Matrix metalloproteinases as therapeutic targets for idiopathic pulmonary fibrosis[J].Am J Respir Cell Mol Biol, 2015, 53(5):585-600.
[29] MCKEOWN S, RICHTER A G, O'KANE C, et al.MMP expression and abnormal lung permeability are important determinants of outcome in IPF[J].Eur Respir J, 2009, 33(1):77-84.
[30] CRAIG V J, QUINTERO P A, FYFE S E, et al.Profibrotic activities for matrix metalloproteinase-8 during bleomycin-mediated lung injury[J].J Immunol, 2013, 190(8):4283-4296.
[31] GARCIA-PRIETO E, GONZALEZ-LOPEZ A, CABRERA S, et al.Resistance to bleomycin-induced lung fibrosis in MMP-8 deficient mice is mediated by interleukin-10[J].PLoS One, 2010, 5(10):e13242.
[32] CRAIG V J, POLVERINO F, LAUCHO-CONTRERAS M E, et al.Mononuclear phagocytes and airway epithelial cells:novel sources of matrix metalloproteinase-8(MMP-8) in patients with idiopathic pulmonary fibrosis[J].PLoS One, 2014, 9(5):e97485.
[33] KIM J Y, CHOENG H C, AHN C, et al.Early and late changes of MMP-2 and MMP-9 in bleomycin-induced pulmonary fibrosis[J].Yonsei Med J, 2009, 50(1):68-77.
[34] BEEH K M, BEIER J, KORNMANN O, et al.Sputum matrix metalloproteinase-9, tissue inhibitor of metalloprotinease-1, and their molar ratio in patients with chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and healthy subjects[J].Respir Med, 2003, 97(6):634-639.
[35] KOBAYASHI T, KIM H, LIU X, et al.Matrix metalloproteinase-9 activates TGF-beta and stimulates fibroblast contraction of collagen gels[J].Am J Physiol Lung Cell Mol Physiol, 2014, 306(11):L1006-1015.
[36] PAPAYANNOPOULOS V.Neutrophil extracellular traps in immunity and disease[J].Nat Rev Immunol, 2018, 18(2):134-147.
[37] DORING Y, SOEHNLEIN O, WEBER C.Neutrophil extracellular traps in atherosclerosis and atherothrombosis[J].Circ Res, 2017, 120(4):736-743.
[38] ALBRENGUES J, SHIELDS M A, NG D, et al.Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice[J].Science, 2018, 361(6409):eaao4227.
[39] LAW S M, GRAY R D.Neutrophil extracellular traps and the dysfunctional innate immune response of cystic fibrosis lung disease:a review[J].J Inflamm(Lond), 2017, 14:29.
[40] BARNADO A, CROFFORD L J, OATES J C.At the bedside:neutrophil extracellular traps(NETs) as targets for biomarkers and therapies in autoimmune diseases[J].J Leukoc Biol, 2016, 99(2):265-278.
[41] CHRYSANTHOPOULOU A, MITROULIS I, APOSTOLIDOU E, et al.Neutrophil extracellular traps promote differentiation and function of fibroblasts[J].J Pathol, 2014, 233(3):294-307.
[42] SUZUKI M, IKARI J, ANAZAWA R, et al.PAD4 deficiency improves bleomycin-induced neutrophil extracellular traps and fibrosis in mouse lung[J].Am J Respir Cell Mol Biol, 2020, 63(6):806-818.
[43] SAFFARZADEH M, JUENEMANN C, QUEISSER M A, et al.Neutrophil extracellular traps directly induce epithelial and endothelial cell death:a predominant role of histones[J].PLoS One, 2012, 7(2):e32366.
[44] YANG H, BIERMANN M H, BRAUNER J M, et al.New insights into neutrophil extracellular traps:mechanisms of formation and role in inflammation[J].Front Immunol, 2016, 7:302.
[45] RADERMECKER C, DETREMBLEUR N, GUIOT J, et al.Neutrophil extracellular traps infiltrate the lung airway, interstitial, and vascular compartments in severe COVID-19[J].J Exp Med, 2020, 217(12):e20201012.
[46] MARTINOD K, WITSCH T, ERPENBECK L, et al.Peptidylarginine deiminase 4 promotes age-related organ fibrosis[J].J Exp Med, 2017, 214(2):439-458. |
